---
title: "Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263434524.md"
description: "The negotiation for the National Medical Insurance Catalog in 2025 officially started today. Reporters on-site learned that around 1:30 PM, the participating companies included Boehringer Ingelheim, Pfizer, Qilu Pharmaceutical, Kangyuan Pharmaceutical, Baile Pharmaceutical, Shengdi Pharmaceutical, Fosun Pharma, and Fresenius Kabi, among others. Earlier in the morning, the participating companies included LIVZON PHARMA, Innovent Biologics, Roche, and AstraZeneca"
datetime: "2025-10-30T06:19:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263434524.md)
  - [en](https://longbridge.com/en/news/263434524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263434524.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263434524.md) | [English](https://longbridge.com/en/news/263434524.md)


# Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue

The negotiation for the national medical insurance catalog in 2025 officially started today. Journalists on site learned that around 1:30 PM, the participating companies included Boehringer Ingelheim, Pfizer, Qilu Pharmaceutical, Kangyuan Pharmaceutical, Baile Pharmaceutical, Shengdi Pharmaceutical, Fosun Pharma, and Fresenius Kabi, among others. Earlier in the morning, the participating companies included LIVZON PHARMA, Innovent Biologics, Roche, and AstraZeneca

### 相關股票

- [LIVZON GROUP (000513.CN)](https://longbridge.com/zh-HK/quote/000513.CN.md)
- [LIVZON PHARMA (01513.HK)](https://longbridge.com/zh-HK/quote/01513.HK.md)
- [Pfizer (PFE.US)](https://longbridge.com/zh-HK/quote/PFE.US.md)

## 相關資訊與研究

- [Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis | PFE Stock News](https://longbridge.com/zh-HK/news/278375686.md)
- [Pfizer Gains Chinese Approval for GLP-1 Weight Management Drug Enochlutide](https://longbridge.com/zh-HK/news/278064724.md)
- [Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs](https://longbridge.com/zh-HK/news/276889928.md)
- [Correction to Roche Shares Article](https://longbridge.com/zh-HK/news/278418696.md)
- [China Clears Weight-Loss Shot As Pfizer Enters Crowded Market](https://longbridge.com/zh-HK/news/278109664.md)